Prestige Biologics shareholders reject 5-for-1 share consolidation at Sept. 30 meeting
At its annual shareholders’ meeting on Sept. 30, 2026, Prestige Biologics’ shareholders rejected a 5-for-1 share consolidation, leaving the capital structure unchanged unless revisited, and also voted down a proposal to change par value per share.